PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study

Donald M. Lyall, Joey Ward, Maciej Banach, George Davey Smith, Jason M. R. Gill, Jill P Pell, Michael V Holmes*, Naveed Sattar*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)

Abstract

Background: PCSK9 inhibitors lower low-density lipoprotein (LDL) cholesterol and are efficacious at reducing vascular disease, however questions remain about potential effects on cognitive function.

Method: We examined the association of genetic variants in PCSK9 with continuous measures of cognitive ability in UK Biobank. Six independent polymorphisms in PCSK9 were used in up to 337,348 individuals.

Results: The PCSK9 allele score was associated with a lower risk of CHD, and worse log reaction time.

Conclusion: We are unable to rule out meaningful associations of PCSK9 genetic variants with cognition, emphasising continued pharmacovigilance for patients currently treated with PCSK9 inhibitors.
Original languageEnglish
JournalArchives of Medical Science
Publication statusPublished - 3 Sep 2020

Fingerprint Dive into the research topics of 'PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study'. Together they form a unique fingerprint.

Cite this